+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gene Therapy Market - Global Forecast 2026-2032- Product Image
Gene Therapy Market - Global Forecast 2026-2032- Product Image
Sale

Gene Therapy Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4858031
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gene Therapy Market is projected to reach USD 16.35 Billion in 2026. It is expected to continue growing at a CAGR of 28.80%, reaching USD 75.92 Billion by 2032.

Gene therapy is moving from a highly specialized research field into a clinically validated treatment model for rare diseases, oncology, hematology, ophthalmology, neurology, and inherited metabolic disorders. The field is supported by a growing base of approved in vivo and ex vivo therapies, including adeno-associated virus (AAV) vectors, lentiviral vectors, and genome-editing approaches. Regulatory milestones, including approvals of retinal dystrophy therapy, spinal muscular atrophy therapy, multiple CAR-T cell therapies, and the first CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia, have strengthened confidence in long-term therapeutic potential.

Demand is being shaped by high unmet medical need, increasing genetic diagnosis rates, orphan drug incentives, newborn screening expansion, and broader clinical pipelines. At the same time, commercialization remains complex because gene therapy requires specialized manufacturing, cold-chain logistics, long-term follow-up, value-based reimbursement, and rigorous safety monitoring. Organizations that can integrate clinical evidence, scalable production, patient access strategy, and regulatory alignment are positioned to lead the next phase of the gene therapy industry.

Transformative Shifts in the Gene Therapy Landscape

The gene therapy landscape is being transformed by the transition from single-product breakthroughs to platform-based development. Sponsors are increasingly using validated vectors, modular manufacturing processes, and disease-area expertise to accelerate programs across related indications. This shift is improving clinical development efficiency while raising expectations for durability, safety, and reproducibility.

Manufacturing capacity has become a strategic differentiator. Viral vector supply constraints, quality control requirements, potency assay complexity, and high cost of goods continue to influence launch timelines and access strategies. In parallel, non-viral delivery, lipid nanoparticles, base editing, prime editing, targeted in vivo delivery, and improved capsid engineering are expanding the competitive field beyond traditional viral vector platforms.

The commercial model is also changing. Payers are demanding evidence of long-term clinical benefit, especially for one-time therapies with high upfront treatment costs. As a result, outcomes-based agreements, installment payment models, registries, and real-world evidence programs are becoming central to gene therapy market access strategy.

Cumulative Impact of Artificial Intelligence in Gene Therapy

Artificial intelligence is creating cumulative value across the gene therapy value chain by improving target identification, vector engineering, sequence optimization, patient stratification, and clinical trial design. AI-enabled models can analyze genomic, transcriptomic, proteomic, imaging, safety, and real-world datasets to identify disease mechanisms and prioritize therapeutic candidates with stronger biological rationale.

In development and manufacturing, AI supports process monitoring, predictive quality analytics, assay optimization, deviation detection, and batch-failure reduction. These capabilities are particularly relevant for viral vector production, where yield variability, impurity profiles, and release testing can affect both cost and supply reliability. AI is also being applied to adverse-event signal detection and long-term follow-up analytics, supporting regulatory compliance for therapies that may require monitoring for years after administration.

The impact is cumulative rather than isolated: each dataset generated during discovery, clinical trials, manufacturing, and post-market surveillance improves future decision-making. Organizations with governed data infrastructure, validated models, privacy-compliant data use, and cross-functional AI adoption are likely to shorten development cycles and strengthen evidence generation.

Key Regional Insights: Gene Therapy Adoption by Region

North America remains the leading region for gene therapy innovation, supported by deep biotechnology financing, advanced academic medical centers, established rare disease advocacy networks, regulatory experience with expedited pathways, and a strong base of contract development and manufacturing organizations. The United States anchors regional activity through clinical trials, regulatory approvals, and commercial launches, while Canada contributes through research networks, cell and gene therapy manufacturing initiatives, and rare disease policy development.

Europe is a major hub for advanced therapy medicinal products, with a dedicated ATMP regulatory framework and strong clinical infrastructure across Germany, France, Italy, Spain, and the United Kingdom. Country-specific health technology assessment processes and pricing negotiations can slow patient access after approval, but the region’s emphasis on real-world evidence, managed entry agreements, and cross-border scientific collaboration is shaping global reimbursement standards for advanced therapies.

Asia-Pacific is expanding rapidly as China, Japan, South Korea, Australia, India, and ASEAN markets invest in biotechnology infrastructure, clinical trial capacity, genomic medicine, and domestic manufacturing. China has become a major center for cell therapy trials and gene-editing research, while Japan’s regenerative medicine framework supports accelerated development pathways and South Korea continues to strengthen biomanufacturing capabilities. Latin America, led by Brazil and Mexico, is building access through specialized centers and regulatory modernization, although affordability, diagnostic coverage, and infrastructure gaps remain important barriers. The Middle East, particularly GCC countries, is investing in precision medicine, genomic screening, and tertiary care, while Africa’s opportunity is tied to genomics capacity, diagnostic access, newborn screening, and partnerships addressing high-burden inherited conditions such as hemoglobinopathies.

Key Group Insights: Strategic Gene Therapy Market Blocs

ASEAN is emerging as a growth corridor for gene therapy through improving hospital infrastructure, rising rare disease awareness, increased genetic testing capacity, and medical tourism in markets such as Singapore, Thailand, and Malaysia. However, reimbursement maturity, local manufacturing depth, and advanced therapy regulatory harmonization remain uneven, making regional partnerships and centers-of-excellence models critical for access.

The GCC is prioritizing precision medicine, genomic screening, and high-acuity specialty care, particularly in Saudi Arabia, the United Arab Emirates, and Qatar. These markets are well positioned to adopt advanced therapies through centralized health systems, national transformation programs, and investment in specialty hospitals, but long-term follow-up systems, outcomes tracking, and cost-management frameworks are essential for sustainable uptake.

The European Union provides one of the most structured regulatory environments through the ATMP framework, while joint clinical assessment under evolving EU health technology assessment rules is expected to influence evidence expectations and access planning. BRICS countries represent a large long-term opportunity due to population scale, genetic disease burden, expanding clinical research, and increasing domestic biotech investment, though access varies widely by healthcare financing model and specialist infrastructure. G7 countries continue to dominate approvals, clinical development, manufacturing quality systems, and reimbursement innovation, while NATO member markets overlap significantly with advanced healthcare systems investing in supply-chain resilience, biosecurity, health security, and domestic advanced therapy manufacturing.

Key Country Insights: Priority Gene Therapy Markets

The United States is the most commercially advanced gene therapy market, with strong regulatory precedent, broad clinical trial activity, specialized treatment centers, rare disease advocacy, and significant biotechnology financing. Canada is strengthening research and manufacturing capacity while addressing access through provincial reimbursement pathways and national rare disease policy initiatives. Mexico and Brazil are important Latin American markets, with Brazil offering the region’s strongest clinical research and regulatory base, while both countries continue to address affordability, referral pathways, genetic testing availability, and specialized treatment-center capacity.

In Europe, the United Kingdom combines scientific leadership with an innovative medicines environment and strong genomic medicine infrastructure, while Germany and France are central to clinical adoption, pricing negotiations, hospital-based delivery, and health technology assessment influence. Italy and Spain have strong specialist networks and experience with managed access for advanced therapies. Russia has scientific capabilities in biomedical research, but geopolitical, regulatory, and supply-chain factors influence international collaboration and access to advanced therapy inputs.

China is one of the most active gene therapy and cell therapy development markets, supported by large patient populations, domestic biotechnology investment, expanding regulatory maturity, and growing hospital-based clinical trial capacity. India offers long-term potential through genetic disease burden, cost-efficient manufacturing, improving genomic diagnostics, and a growing biotech sector. Japan provides a favorable environment for regenerative medicine and advanced therapies, South Korea is investing heavily in biomanufacturing and translational research, and Australia contributes through clinical trial excellence, hospital networks, rare disease programs, and government-supported medical research.

Actionable Recommendations for Gene Therapy Industry Leaders

Industry leaders should prioritize scalable manufacturing early in development, including vector process optimization, analytical validation, potency assay strategy, and dual-sourcing strategies for critical raw materials. Robust chemistry, manufacturing, and controls planning is essential because quality comparability, batch consistency, and release testing reliability can determine regulatory timelines and commercial readiness.

Market access should be built into the clinical strategy rather than added after approval. Sponsors need endpoints that demonstrate durable patient benefit, registries that support long-term evidence generation, and payer engagement models that address high upfront therapy costs. Outcomes-based reimbursement, staged payments, annuity-style models, and risk-sharing agreements should be evaluated where legally and operationally feasible.

Organizations should also invest in AI-enabled data infrastructure, decentralized patient identification, genetic testing partnerships, newborn screening alignment, and centers-of-excellence networks. These capabilities improve trial recruitment, shorten diagnostic delays, and support safe administration in real-world settings. Strategic alliances with academic institutions, manufacturing partners, diagnostic providers, patient organizations, and regional health systems can accelerate responsible global expansion.

Research Methodology

The research methodology is developed using a triangulated research approach that combines regulatory intelligence, clinical trial analysis, public disclosures, scientific literature, patent trends, reimbursement developments, and regional healthcare infrastructure assessment. Priority sources include public regulatory databases, peer-reviewed publications, health technology assessment documents, public filings, treatment guidelines, recognized clinical trial registries, and government healthcare policy documents.

The methodology emphasizes verified and current evidence rather than speculative market claims. Insights are cross-checked across multiple source categories to evaluate approval momentum, pipeline direction, technology adoption, manufacturing constraints, patient access dynamics, and safety monitoring requirements. Regional, group, and country assessments consider regulatory maturity, financing capacity, treatment-center infrastructure, genetic testing availability, long-term follow-up systems, and policy support for advanced therapies.

Conclusion: Strategic Outlook for Gene Therapy

Gene therapy is entering a decisive growth phase as scientific validation, regulatory experience, and patient demand converge. The industry’s next leaders will be those that combine breakthrough biology with manufacturability, safety, durable outcomes, and credible reimbursement evidence.

Artificial intelligence, next-generation delivery systems, genomic diagnostics, and global manufacturing investment are expected to reshape development productivity and access. However, the sector must continue to address affordability, long-term monitoring, equitable patient identification, and scalable delivery through qualified treatment centers. For industry leaders, the strategic priority is clear: build integrated platforms that connect discovery, manufacturing, clinical evidence, safety surveillance, and market access from the earliest stages of development.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gene Therapy Market, by Vector Type
7.1. Introduction
7.2. Non-Viral Vectors
7.2.1. Lipofection
7.2.2. Plasmid DNA
7.3. Viral Vectors
7.3.1. Adeno-Associated Virus (AAV) Vectors
7.3.2. Adenovirus Vectors
7.3.3. Herpes Simplex Virus (HSV) Vectors
7.3.4. Retrovirus Vectors
8. Gene Therapy Market, by Therapy Type
8.1. Introduction
8.2. Gene Replacement Therapy
8.3. Gene Silencing Therapy
8.4. Gene Editing Therapy
8.5. Gene Augmentation Therapy
8.6. Cell-Based Gene Therapy
9. Gene Therapy Market, by Target Genome
9.1. Introduction
9.2. DNA Modification
9.3. RNA Modification
10. Gene Therapy Market, by Delivery Mode
10.1. Introduction
10.2. Ex Vivo
10.3. In Vivo
11. Gene Therapy Market, by Route of Administration
11.1. Introduction
11.2. Intramuscular
11.3. Intraocular
11.4. Intravenous
12. Gene Therapy Market, by Patient Type
12.1. Introduction
12.2. Adult Patients
12.3. Pediatric Patients
13. Gene Therapy Market, by Therapeutic Area
13.1. Introduction
13.2. Cardiovascular Diseases
13.2.1. Coronary Artery Disease
13.2.2. Heart Failure
13.3. Infectious Diseases
13.3.1. Hepatitis B
13.3.2. HIV
13.4. Monogenic Disorders
13.4.1. Cystic Fibrosis
13.4.2. Hemophilia
13.4.3. Sickle Cell Anemia
13.5. Oncological Disorders
13.5.1. Hematological Malignancies
13.5.2. Solid Tumors
14. Gene Therapy Market, by End-User
14.1. Introduction
14.2. Contract Research Organizations
14.3. Hospitals & Clinics
14.4. Pharmaceutical & Biotech Companies
14.5. Research Institutes
15. Gene Therapy Market, by Region
15.1. Asia-Pacific
15.2. North America
15.3. Latin America
15.4. Europe
15.5. Middle East
15.6. Africa
16. Gene Therapy Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Gene Therapy Market, by Country
17.1. United States
17.2. China
17.3. Germany
17.4. United Kingdom
17.5. Japan
17.6. India
17.7. France
17.8. Canada
17.9. Brazil
17.10. Australia
17.11. Spain
17.12. Italy
17.13. Russia
17.14. Mexico
17.15. South Korea
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. Abeona Therapeutics Inc.
19.2. Adaptimmune Therapeutics PLC
19.3. Adverum Biotechnologies, Inc.
19.4. AGC Biologics
19.5. Alnylam Pharmaceuticals, Inc.
19.6. American Gene Technologies Inc.
19.7. Amgen Inc.
19.8. AnGes, Inc.
19.9. Astellas Pharma Inc.
19.10. Biogen Inc.
19.11. bluebird bio, Inc.
19.12. Cellectis S.A.
19.13. CRISPR Therapeutics AG
19.14. Danaher Corporation
19.15. Editas Medicine, Inc.
19.16. F. Hoffmann-La Roche Ltd.
19.17. Gilead Sciences, Inc.
19.18. Intellia Therapeutics
19.19. Ionis Pharmaceuticals, Inc.
19.20. Johnson & Johnson
19.21. Merck KGaA
19.22. Mustang Bio, Inc.
19.23. Novartis AG
19.24. Orchard Therapeutics PLC
19.25. Poseida Therapeutics, Inc.
19.26. Sangamo Therapeutics, Inc.
19.27. Sarepta Therapeutics, Inc.
19.28. Sibiono GeneTech Co. Ltd.
19.29. Syncona Limited
19.30. ViGeneron GmbH
19.31. Voyager Therapeutics Inc.
List of Figures
FIGURE 1. GLOBAL GENE THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL GENE THERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL GENE THERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL GENE THERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025 VS 2032 (%)
FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 19. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL GENE THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL GENE THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL GENE THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL LIPOFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL LIPOFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL LIPOFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PLASMID DNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PLASMID DNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PLASMID DNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ADENO-ASSOCIATED VIRUS (AAV) VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ADENO-ASSOCIATED VIRUS (AAV) VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ADENO-ASSOCIATED VIRUS (AAV) VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ADENOVIRUS VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ADENOVIRUS VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ADENOVIRUS VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL RETROVIRUS VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL RETROVIRUS VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL RETROVIRUS VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL GENE REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL GENE REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL GENE REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GENE SILENCING THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GENE SILENCING THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GENE SILENCING THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL GENE AUGMENTATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL GENE AUGMENTATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL GENE AUGMENTATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CELL-BASED GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CELL-BASED GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CELL-BASED GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL DNA MODIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DNA MODIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL DNA MODIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL RNA MODIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL RNA MODIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL RNA MODIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL INTRAOCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL INTRAOCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL INTRAOCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HIV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HIV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL MONOGENIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL MONOGENIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL MONOGENIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HEMOPHILIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL HEMOPHILIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL HEMOPHILIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL SICKLE CELL ANEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL SICKLE CELL ANEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL SICKLE CELL ANEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ONCOLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL ONCOLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ONCOLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 174. EUROPE GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. EUROPE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 176. EUROPE GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 177. EUROPE GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 178. EUROPE GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 179. EUROPE GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 180. EUROPE GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 181. EUROPE GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 182. EUROPE GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 183. EUROPE GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 184. EUROPE GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 185. EUROPE GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 186. EUROPE GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 187. EUROPE GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 188. EUROPE GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 203. MIDDLE EAST GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 204. AFRICA GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 205. AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 206. AFRICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 207. AFRICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 208. AFRICA GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 209. AFRICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 210. AFRICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 211. AFRICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 212. AFRICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 213. AFRICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 214. AFRICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 215. AFRICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 216. AFRICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 217. AFRICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 218. AFRICA GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 219. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. ASEAN GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 221. ASEAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 222. ASEAN GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 223. ASEAN GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 224. ASEAN GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 225. ASEAN GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 226. ASEAN GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 227. ASEAN GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. ASEAN GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 229. ASEAN GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 230. ASEAN GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 231. ASEAN GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 232. ASEAN GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 233. ASEAN GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 234. ASEAN GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 235. GCC GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 236. GCC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 237. GCC GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 238. GCC GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 239. GCC GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 240. GCC GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 241. GCC GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 242. GCC GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 243. GCC GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 244. GCC GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 245. GCC GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 246. GCC GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 247. GCC GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 248. GCC GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 249. GCC GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 265. BRICS GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 266. BRICS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 267. BRICS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 268. BRICS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 269. BRICS GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 270. BRICS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 271. BRICS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 272. BRICS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 273. BRICS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 274. BRICS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 275. BRICS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 276. BRICS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 277. BRICS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 278. BRICS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 279. BRICS GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 280. G7 GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 281. G7 GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 282. G7 GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 283. G7 GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 284. G7 GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 285. G7 GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 286. G7 GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 287. G7 GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 288. G7 GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 289. G7 GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 290. G7 GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 291. G7 GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 292. G7 GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 293. G7 GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 294. G7 GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 295. NATO GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 296. NATO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 297. NATO GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 298. NATO GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 299. NATO GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 300. NATO GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 301. NATO GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 302. NATO GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 303. NATO GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 304. NATO GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 305. NATO GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 306. NATO GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 307. NATO GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 308. NATO GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 309. NATO GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 310. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 311. UNITED STATES GENE THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 313. UNITED STATES GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 314. UNITED STATES GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 315. UNITED STATES GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 316. UNITED STATES GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 317. UNITED STATES GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 318. UNITED STATES GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 319. UNITED STATES GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 322. UNITED STATES GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 324. UNITED STATES GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 325. UNITED STATES GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 326. CHINA GENE THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. CHINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 328. CHINA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 329. CHINA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 330. CHINA GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 331. CHINA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 332. CHINA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 333. CHINA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 334. CHINA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 335. CHINA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 336. CHINA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 337. CHINA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 338. CHINA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 339. CHINA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 340. CHINA GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 341. GERMANY GENE THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 342. GERMANY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 343. GERMANY GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 344. GERMANY GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 345. GERMANY GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 346. GERMANY GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 347. GERMANY GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 348. GERMANY GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 349. GERMANY GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 350. GERMANY GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 351. GERMANY GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 352. GERMANY GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 353. GERMANY GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 354. GERMANY GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 355. GERMANY GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 356. UNITED KINGDOM GENE THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 357. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 358. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 359. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2017-2032 (USD MILLION)
TABLE 360. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 361. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2017-2032 (USD MILLION)
TABLE 362. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 363. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 364. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 365. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 366. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 367. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 368. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 369. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 370. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 371. JAPAN GENE THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 372. JAPAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2017-2032 (USD MILLION)
TABLE 373. JAPAN GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2017-2032 (USD M

Companies Mentioned

  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum Biotechnologies, Inc.
  • AGC Biologics
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • bluebird bio, Inc.
  • Cellectis S.A.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • ViGeneron GmbH
  • Voyager Therapeutics Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 16.35 Billion
Forecasted Market Value ( USD ) by 2032 $ 75.92 Billion
Compound Annual Growth Rate28.8%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Cell & Gene Therapy Manufacturing Services Market - Global Forecast 2026-2032 - Product Image

Cell & Gene Therapy Manufacturing Services Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Cell & Gene Therapy Clinical Trials Market - Global Forecast 2026-2032 - Product Image

Cell & Gene Therapy Clinical Trials Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Gene Therapy Clinical Trial Services - Global Strategic Business Report - Product Image

Gene Therapy Clinical Trial Services - Global Strategic Business Report

  • Report
  • 414 Pages
  • Global
From
Cancer Gene Therapy - Global Strategic Business Report - Product Image

Cancer Gene Therapy - Global Strategic Business Report

  • Report
  • 237 Pages
  • Global
From
Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-Users and Key Geographical Regions - Product Image

Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-Users and Key Geographical Regions

  • Report
  • 343 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.